NASH Drug Development Questions? US FDA Has Many Of The Answers

From biomarkers to treatment effect size, agency officials respond to some of more than a hundred questions that poured in during a webinar on development of drugs to treat the liver disease.

Liver
FDA officials address questions about development of drugs for NASH liver disease • Source: Shutterstock

The US Food and Drug Administration was deluged with questions during a webinar on the development of new drugs to treat non-alcoholic steatohepatitis (NASH), showing how hot the area is in pharma R&D and the issues of concern to sponsors, from the use of biomarkers to the length of trials.

In opening the 29 January webinar, Toru Matsubayashi, a medical reviewer in the Division of Hepatology and Nutrition, noted some...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership